

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner



Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

DUR COMMITTEE AGENDA

Date: Tuesday, March 10, 2020
Time: 5:30PM to 8:30PM
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

- 1) Call to Order
- 2) MaineCare Updates
- 3) Public Comments
- 4) Old Business
 - Approve December Meeting Minutes
- 5) Closed Session
 - Drug Financial Information Review
- 6) Revised clinical criteria
 - Biosimilars
 - Kanjinti
 - Ogivri
 - Ruxience
 - Ziextenzo
 - Truxima
 - Zirabev
- 7) New Business (open session)
 - Retro DUR
 - Data Presentation: Use of statins in members with diabetes mellitus.
 - Data Presentation: Use of Buprenorphine for MAT
 - Introduce: Prescriber PDL Compliance (pick 6 categories)
 - New Drug Review

Absorica LD
Adakveo
Amzeeq
Asceniv
Beovu
Brukinsa
Clovique
Enhertu
Esperoct

Eylea
Givlaari
Gloperba
Oxbryta
Padcev
Pretomanid
Reblozyl
Recarbrio
Reyvow

Secuado
Tazverik
Tepezza
Ubrelyv
Vumerity
Vyondys
Wakix
Zolgensma

8) FDA Safety Alerts

FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)

https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin?utm_campaign=FDA%20MedWatch%20-%20gabapentin%20and%20pregabalin%29%3A%20Drug%20Safety%20Communication&utm_medium=email&utm_source=Eloqua

INVIRASE: pregnancy and lactation label updates

<http://s2027422842.t.en25.com/e/es?s=2027422842&e=286692&elqTrackId=376c7bc788024cd5a73d955f2e3dcdbdc&elq=4e689a40467c423291cd63c181b0c7b6&elqaid=10694&elqat=1>

KALETRA and NORVIR: drug-drug interaction updates

<http://s2027422842.t.en25.com/e/es?s=2027422842&e=286712&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=ae9e9ecc8df44044bd83dd763895863b&elqaid=10697&elqat=1>

FDA requests withdrawal of bacitracin for injection from market

https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-bacitracin-injection-market?utm_campaign=FDA%20requests%20withdrawal%20of%20bacitracin%20for%20injection%20from%20market&utm_medium=email&utm_source=Eloqua

FDA launches mobile-friendly database with information on life-saving HIV drugs as part of ongoing mission to empower the public through increased access to information and data

https://www.fda.gov/news-events/press-announcements/fda-launches-mobile-friendly-database-information-life-saving-hiv-drugs-part-ongoing-mission-empower?utm_campaign=FDA%20launches%20mobile-friendly%20database%20with%20information%20on%20life-saving%20HIV%20drugs&utm_medium=email&utm_source=Eloqua

Clozaril, Fazacllo ODT, Versacloz (clozapine): Drug Safety Communication - FDA Strengthens Warning That Untreated Constipation Can Lead to Serious Bowel Problems

https://www.fda.gov/safety/medical-product-safety-information/clozaril-fazacllo-odt-versacloz-clozapine-drug-safety-communication-fda-strengthens-warning-untreated?utm_campaign=FDA%20MedWatch%3AClozaril%2C%20Fazacllo%20ODT%2C%20Versacloz%20%28clozapine%29-%20Drug%20Safety%20Communication&utm_medium=email&utm_source=Eloqua

9) Next Meeting (Tuesday, June 16, 2020 (from 5:30pm to 8:30pm)

10) Adjournment: 8:30PM